Literature DB >> 25941620

Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer.

Max Schnurr1, Peter Duewell1.   

Abstract

RIG-I-like helicases (RLH) are cytosolic sensors for viral RNA inducing type I interferon production. We found that pancreatic cancer cells express functional RLH and are susceptible to RLH-induced apoptosis via intrinsic and extrinsic pathways. Tumor cells displayed features of immunogenic cell death resulting in dendritic cell activation, enhanced antigen cross-presentation and efficient tumor control in vivo.

Entities:  

Keywords:  ATP, adenosine triphosphate; CD, cluster of differentiation; CTL, cytotoxic T lymphocytes; CXCL10, C-X-C motif chemokine 10; DC, dendritic cell; HMGB1, high-mobility group box protein I; IFN, interferon; IRF, interferon regulatory factor; MAPK, mitogen-activated protein kinase; MDA5, melanoma differentiation-associated protein 5; MDSC, myeloid-derived suppressor cell; RAGE, receptor for advanced glycation endproducts; RIG-I, retinoic acid-inducible gene I; RIG-I-like helicases; RLH, RIG-I-like helicase; TLR, toll-like receptor; fas; hsp70, heat shock protein 70; immunogenic cell death; pancreatic cancer; type I IFN

Year:  2014        PMID: 25941620      PMCID: PMC4292725          DOI: 10.4161/21624011.2014.955687

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  10 in total

1.  APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions.

Authors:  Luigia Pace; Sara Vitale; Beatrice Dettori; Cecilia Palombi; Valentina La Sorsa; Filippo Belardelli; Enrico Proietti; Gino Doria
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

Review 2.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Lei Zheng; Jing Xue; Elizabeth M Jaffee; Aida Habtezion
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 3.  Immune signaling by RIG-I-like receptors.

Authors:  Yueh-Ming Loo; Michael Gale
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

4.  CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Christine Zoglmeier; Helen Bauer; Daniel Noerenberg; Georg Wedekind; Philipp Bittner; Nadja Sandholzer; Moritz Rapp; David Anz; Stefan Endres; Carole Bourquin
Journal:  Clin Cancer Res       Date:  2011-01-13       Impact factor: 12.531

Review 5.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

6.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Authors:  Robert Besch; Hendrik Poeck; Tobias Hohenauer; Daniela Senft; Georg Häcker; Carola Berking; Veit Hornung; Stefan Endres; Thomas Ruzicka; Simon Rothenfusser; Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

7.  Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.

Authors:  Jonathan Ellermeier; Jiwu Wei; Peter Duewell; Sabine Hoves; Mareike R Stieg; Tina Adunka; Daniel Noerenberg; Hans-Joachim Anders; Doris Mayr; Hendrik Poeck; Gunther Hartmann; Stefan Endres; Max Schnurr
Journal:  Cancer Res       Date:  2013-01-21       Impact factor: 12.701

8.  RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.

Authors:  P Duewell; A Steger; H Lohr; H Bourhis; H Hoelz; S V Kirchleitner; M R Stieg; S Grassmann; S Kobold; J T Siveke; S Endres; M Schnurr
Journal:  Cell Death Differ       Date:  2014-07-11       Impact factor: 15.828

9.  Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation.

Authors:  Gang Meng; Mao Xia; Chun Xu; Dongmei Yuan; Max Schnurr; Jiwu Wei
Journal:  Int J Cancer       Date:  2013-12-02       Impact factor: 7.396

10.  5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.

Authors:  Hendrik Poeck; Robert Besch; Cornelius Maihoefer; Marcel Renn; Damia Tormo; Svetlana Shulga Morskaya; Susanne Kirschnek; Evelyn Gaffal; Jennifer Landsberg; Johannes Hellmuth; Andreas Schmidt; David Anz; Michael Bscheider; Tobias Schwerd; Carola Berking; Carole Bourquin; Ulrich Kalinke; Elisabeth Kremmer; Hiroki Kato; Shizuo Akira; Rachel Meyers; Georg Häcker; Michael Neuenhahn; Dirk Busch; Jürgen Ruland; Simon Rothenfusser; Marco Prinz; Veit Hornung; Stefan Endres; Thomas Tüting; Gunther Hartmann
Journal:  Nat Med       Date:  2008-11-02       Impact factor: 53.440

  10 in total
  4 in total

1.  CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.

Authors:  Lena M Kranz; Matthias Birtel; Christina Krienke; Christian Grunwitz; Jutta Petschenka; Kerstin C Reuter; Niels van de Roemer; Fulvia Vascotto; Mathias Vormehr; Sebastian Kreiter; Mustafa Diken
Journal:  Hum Vaccin Immunother       Date:  2015-07-17       Impact factor: 3.452

2.  Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncotarget       Date:  2017-01-24

Review 3.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

4.  Nucleic Acid Immunity.

Authors:  G Hartmann
Journal:  Adv Immunol       Date:  2016-12-15       Impact factor: 3.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.